<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472833</url>
  </required_header>
  <id_info>
    <org_study_id>VITdCUT 1.3 - 21022018</org_study_id>
    <nct_id>NCT03472833</nct_id>
  </id_info>
  <brief_title>High-dose Vitamin D3 in Pancreas Cancer</brief_title>
  <acronym>VITdCUT</acronym>
  <official_title>Influence of High Dose Vitamin D3 Intake on Outcome in Pancreatic Cancer Surgery: Prospective, Randomized, Open, Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different studies have shown that a deficiency in vitamin D (≤20ng/mL) results in higher&#xD;
      rates in morbidity and mortality rates in cancer patients. Clinical studies investigated and&#xD;
      demonstrated altered vitamin d tissue in pancreatic cancer. But there is no prospective study&#xD;
      evaluating the beneficiary effects of oral supplementation of vitamin d in altered vitamin d&#xD;
      tissue from pancreatic cancer. We want to examine the effect of a high dose vitamin D3&#xD;
      therapy vs. a standard base dose vitamin D3 therapy in pancreas cancer patients with a&#xD;
      vitamin D deficiency. In case of benefit in our results we could implement vitamin D3 as a&#xD;
      supportive standard therapy in pancreatic cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>25(OH) vitamin D</measure>
    <time_frame>Day 60</time_frame>
    <description>Blood level of Vitamin D3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>25(OH) vitamin D</measure>
    <time_frame>Day 30</time_frame>
    <description>Blood level of Vitamin D3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,25(OH)2D vitamin D</measure>
    <time_frame>Day 30</time_frame>
    <description>Blood level of 1,25(OH)2D vitamin D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,25(OH)2D vitamin D</measure>
    <time_frame>Day 60</time_frame>
    <description>Blood level of 1,25(OH)2D vitamin D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Calcium</measure>
    <time_frame>Day 30</time_frame>
    <description>Calcium level in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Calcium</measure>
    <time_frame>Day 60</time_frame>
    <description>Calcium level in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>Day 30</time_frame>
    <description>Bone marker measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>Day 60</time_frame>
    <description>Bone marker measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-crosslaps</measure>
    <time_frame>Day 30</time_frame>
    <description>Bone marker measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-crosslaps</measure>
    <time_frame>Day 60</time_frame>
    <description>Bone marker measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium</measure>
    <time_frame>Day 60</time_frame>
    <description>blood measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium</measure>
    <time_frame>Day 30</time_frame>
    <description>blood measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ionized calcium</measure>
    <time_frame>Day 30</time_frame>
    <description>blood measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ionized calcium</measure>
    <time_frame>Day 60</time_frame>
    <description>blood measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine</measure>
    <time_frame>Day 30</time_frame>
    <description>blood measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine</measure>
    <time_frame>Day 60</time_frame>
    <description>blood measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphate</measure>
    <time_frame>Day 60</time_frame>
    <description>blood measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphate</measure>
    <time_frame>Day 30</time_frame>
    <description>blood measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>60-day mortality</measure>
    <time_frame>Day 60</time_frame>
    <description>Number of patients who die in the specified timeframe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>Day 60</time_frame>
    <description>Hospital stay in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital readmission</measure>
    <time_frame>Day 60</time_frame>
    <description>Number of readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepcidin</measure>
    <time_frame>Day 30</time_frame>
    <description>blood level marker for iron status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepcidin</measure>
    <time_frame>Day 60</time_frame>
    <description>blood level marker for iron status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaire</measure>
    <time_frame>Day 30</time_frame>
    <description>evaluated by EORTC questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaire</measure>
    <time_frame>Day 60</time_frame>
    <description>evaluated by EORTC questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>High-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with high dose oral vitamin D3 supplementation.&#xD;
1 drop equals 400 I.U. This group will get 180.000 I.U. on day 1, and then 4000 I.U. per day for 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention with standard dose oral vitamin D3 supplementation.&#xD;
1 drop equals 400 I.U. This group will get 800 I.U. per day for 60 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose</intervention_name>
    <description>Patients will receive a high dose - 180.000 I.U. (1 drop equals 400 I.U.) of Vitamin D3 orally on day 1, and then 4000 I.U. for 60 days</description>
    <arm_group_label>High-dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose</intervention_name>
    <description>Patients will receive a standard dose - 800 I.U. (equals 2 drops) of Vitamin D3 orally for 60 days</description>
    <arm_group_label>Standard-dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        both sexes&#xD;
&#xD;
          -  vitamin D deficiency(≤20ng/ml)&#xD;
&#xD;
          -  patients&gt;18 years of age&#xD;
&#xD;
          -  pancreatic cancer&#xD;
&#xD;
          -  surgical intervention/non-surgical intervention&#xD;
&#xD;
          -  signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients&lt;18 years of age&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  contraindication for oral vitamin D intake&#xD;
&#xD;
          -  hypercalcemia (&gt; 2.65 mmol/l total calcium and/or &gt; 1.35 mmol/l ionized calcium at&#xD;
             screening)&#xD;
&#xD;
          -  other ongoing vitamin D conducted trial&#xD;
&#xD;
          -  known kidney stones, active tuberculosis or sarcoidosis (in the last 12 months)&#xD;
&#xD;
          -  metastasized pancreatic cancer&#xD;
&#xD;
          -  normal vitamin D serum levels&#xD;
&#xD;
          -  missing written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Kornprat, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Departement for General Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erwin Mathew, Dr. med.</last_name>
    <phone>+4331638581548</phone>
    <email>erwin.mathew@medunigraz.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwin Mathew, Dr. med.</last_name>
      <phone>+4331638581548</phone>
      <email>erwin.mathew@medunigraz.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>V</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

